Valuation: Theraclion

Market Cap 50.08M 57.29M 46.31M 42.5M 80.43M 5.52B 81.83M 552M 217M 2.7B 215M 210M 9.31B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 57.93M 66.28M 53.58M 49.16M 93.04M 6.39B 94.66M 639M 251M 3.12B 249M 243M 10.77B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
Current month-21.18%
3 months+45.97%
6 months+12.79%
Current year+14.73%
Current year 0.44
Extreme 0.435
0.87
1 year 0.36
Extreme 0.363
0.94
3 years 0.14
Extreme 0.1445
0.94
5 years 0.14
Extreme 0.1445
0.94
10 years 0.14
Extreme 0.1445
0.94
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 13/02/2019
Director/Board Member - 01/02/2018
Chairman - 08/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.82% - - 56.03M
+1.48%+3.52%+30.48%+3.41% 199B
+2.10%+4.61%+6.06%-13.77% 142B
+3.43%-2.24%-21.52%+13.70% 138B
+3.67%-0.82%-56.76%-15.19% 63.97B
+0.65%-3.82%+15.37%-5.19% 50.25B
+1.18%+2.66%-23.86%-31.97% 44.33B
+1.03%+1.88%+19.99%+15.10% 38.05B
+0.87%+0.28%+30.61%+40.16% 36.81B
+3.96%+1.55%-12.92%-19.08% 28.75B
Average +0.80%-0.50%-1.40%-1.43% 82.33B
Weighted average by Cap. +0.42%+0.18%+2.10%-0.72%

Financials

2024 2025
Net sales 830K 950K 768K 705K 1.33M 91.52M 1.36M 9.16M 3.6M 44.69M 3.57M 3.49M 154M 652K 746K 603K 553K 1.05M 71.88M 1.07M 7.19M 2.82M 35.1M 2.8M 2.74M 121M
Net income -5.76M -6.59M -5.32M -4.89M -9.25M -635M -9.41M -63.5M -24.94M -310M -24.73M -24.19M -1.07B -5.69M -6.51M -5.26M -4.83M -9.14M -627M -9.3M -62.76M -24.65M -306M -24.45M -23.91M -1.06B
Net Debt 3.41M 3.9M 3.15M 2.89M 5.48M 376M 5.57M 37.62M 14.78M 184M 14.65M 14.33M 634M 7.85M 8.98M 7.26M 6.66M 12.61M 866M 12.83M 86.6M 34.02M 423M 33.73M 32.99M 1.46B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change
16/07/26 0.6700 0.00%
15/07/26 €0.6700 -1.33%
14/07/26 €0.6790 +1.04%
13/07/26 €0.6720 0.00%
10/07/26 €0.6720 +1.82%

Annual profits - Rate of surprise